Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL533056 | 0.84 | DBH (0.33) | KDM4EALDH1A1 | |
| SCHEMBL233448 | 0.84 | KDM4E (0.36) | TAS1R3TAS1R1TAS1R2KDM4EALDH1A1 | |
| SCHEMBL943527 | 0.76 | ALDH1A1 (0.37) | KDM4EALDH1A1HSD17B10PTGS2 | |
| SCHEMBL2286065 | 0.76 | KDM4E (0.31) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL2284682 | 0.76 | ACHE (0.30) | — | |
| SCHEMBL944353 | 0.76 | ACHE (0.34) | PTGS2 | |
| SCHEMBL2289380 | 0.74 | CA2 (0.40) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL2285289 | 0.74 | CA2 (0.40) | — | |
| SCHEMBL2291636 | 0.74 | MAPT (0.34) | — | |
| SCHEMBL15390519 | 0.71 | CYP11B1 (0.33) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200405696-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-31 | — | — | US | claimed |
| CN-111601810-A | Inhibitors of indoleamine 2, 3-dioxygenase and/or tryptophan 2, 3-dioxygenase | 爱杜西亚药品有限公司 | 2020-08-28 | — | — | CN | claimed |
| US-20200405696-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-31 | — | — | US | disclosed |
| CN-111601810-A | Inhibitors of indoleamine 2, 3-dioxygenase and/or tryptophan 2, 3-dioxygenase | 爱杜西亚药品有限公司 | 2020-08-28 | — | — | CN | disclosed |
| EP-3071560-B1 | N-ACYLIMINO HETEROCYCLIC COMPOUNDS | BASF SE (DE) | 2018-01-10 | — | — | EP | disclosed |
| EP-2352371-B1 | SAFENING 4-AMINO-3-CHLORO-6-(4-CHLORO-2-FLUORO-3-METHOXYPHENYL)-2-PYRIDINECARBOXYLATE HERBICIDE INJURY ON DIRECT SEEDED AND TRANSPLANTED PADDY RICE | DOW AGROSCIENCES LLC (US) | 2017-12-20 | — | — | EP | disclosed |
| US-9783523-B2 | N-acylimino heterocyclic compounds | BASF SE (DE) | 2017-10-10 | — | — | US | disclosed |
| US-20160297793-A1 | N-ACYLIMINO HETEROCYCLIC COMPOUNDS | BASF SE (DE) | 2016-10-13 | — | — | US | disclosed |
| EP-2435420-B1 | Pyrazinylpyrazoles | BAYER CROPSCIENCE AG (DE) | 2013-04-03 | — | — | EP | disclosed |
| US-20120190687-A1 | Pyrazinylpyrazoles | BAYER CROPSCIENCE AG | 2012-07-26 | — | — | US | disclosed |
| US-8008232-B2 | Such as N-(3',4'-dichlorobiphenyl-2-yl)-5-chloro-1,3-dimethyl-1H-pyrazole-4-carboxamide; seeds | BASF AKTIENGESELLSCHAFT (DE) | 2011-08-30 | — | — | US | disclosed |
| US-7989394-B2 | Substituted 1-(azolin-2-yl)-amino-2-aryl-1-hetaryl-ethane compounds | BASF SE (DE) | 2011-08-02 | — | — | US | disclosed |
| US-20090131256-A1 | Substituted 1-(azolin-2-yl)-amino-2-aryl-1-hetaryl-ethane Compounds | BASF SE (DE) | 2009-05-21 | — | — | US | disclosed |
| US-20080153707-A1 | Pyrazolecarboxanilides, Process for Their Preparation and Compositions Comprising Them for Controlling Harmful Fungi | BASF AKITENGESELLSCHAFT (DE) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153707-A1 | Pyrazolecarboxanilides, Process for Their Preparation and Compositions Comprising Them for Controlling Harmful Fungi | CBR3, C1S, PYM1 | TAS1R3 2128/4885TAS1R1 3036/4885TAS1R2 3029/4885 |
| US-20120190687-A1 | Pyrazinylpyrazoles | CYP4F3, CYP4B1, CYP1A2 | TAS1R3 3771/4885TAS1R1 4573/4885TAS1R2 4161/4885 |
| US-20200405696-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDO2, TDO2, IDO1 | TAS1R3 4362/4885TAS1R1 4618/4885TAS1R2 4312/4885 |
| US-20090131256-A1 | Substituted 1-(azolin-2-yl)-amino-2-aryl-1-hetaryl-ethane Compounds | AAAS, AIPL1, ATXN2 | TAS1R3 1246/4885TAS1R1 890/4885TAS1R2 683/4885 |
| US-20160297793-A1 | N-ACYLIMINO HETEROCYCLIC COMPOUNDS | CBR3, C5, ALOX5 | TAS1R3 2599/4885TAS1R1 3873/4885TAS1R2 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.